The Journal of dermatological treatment最新文献

{"title":"Levels of several inflammatory cytokines in acne patients before and after isotretinoin therapy: a randomized, controlled clinical trial.","authors":"Wanling Qi, Ruie Wang, Saleh Mahmoud Saleh Khasawneh, Fangyuan Hui, Yan Liu","doi":"10.1080/09546634.2025.2540594","DOIUrl":"10.1080/09546634.2025.2540594","url":null,"abstract":"<p><strong>Introduction: </strong>Acne vulgaris is a chronic inflammatory skin disease, and the inflammatory cytokines play a significant role in its pathophysiology. At present, oral isotretinoin is considered as the most effective treatment for acne. However, its specific anti-inflammatory mechanisms are only partially understood.</p><p><strong>Methods: </strong>The research included 75 patients with acne severity levels II, III and IV together with 25 healthy participants in this prospective controlled clinical trial. Patients received 20 mg/day oral isotretinoin for eight weeks. The research team evaluated inflammatory cytokine levels (IL-8, IL-36, TNF-α, TSLP, and TWEAK) at the beginning and end of the study.</p><p><strong>Results: </strong>The levels of IL-8, IL-36, TNF-α, TSLP, and TWEAK were found to be significantly higher in acne patients as compared to controls (<i>p</i> < 0.05). IL-8, IL-36, and TWEAK levels were found to be significantly decreased after 8 weeks of isotretinoin treatment (<i>p</i> < 0.05). There was no correlation found between the severity of acne and inflammatory cytokine levels (<i>p</i> > 0.05).</p><p><strong>Conclusion: </strong>The anti-inflammatory effects of isotretinoin in acne patients result from its ability to decrease serum levels of inflammatory cytokines (IL-8, IL-36, TNF-α, TSLP, and TWEAK).</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2540594"},"PeriodicalIF":3.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144755467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Upadacitinib in daily practice for refractory atopic dermatitis in adolescents: a case series of the BioDay registry.","authors":"Florence Vroman, Lisa P van der Rijst, Octavian I Bacoş-Cosma, Nicolaas P A Zuithoff, Marijke Kamsteeg, Paula P M van Lumig, Laura Loman, Marie-Louise L A Schuttelaar, Marjolein S de Bruin-Weller, Marlies de Graaf","doi":"10.1080/09546634.2025.2539282","DOIUrl":"https://doi.org/10.1080/09546634.2025.2539282","url":null,"abstract":"<p><strong>Purpose: </strong>Upadacitinib is approved for treating moderate-to-severe atopic dermatitis (AD) aged ≥12 years. We evaluated upadacitinib's effectiveness and safety in AD adolescents in daily practice.</p><p><strong>Materials and methods: </strong>Fifteen adolescent AD patients from the BioDay registry, treated with upadacitinib 15 mg once daily were evaluated at baseline and after 4, 8, 16, and 28 weeks. Effectiveness was assessed using Eczema Area and Severity Index (EASI) score and Investigator Global Assessment (IGA) score. Patient-reported outcomes included Numeric Rating Scale (NRS) for pruritus and presence of sleep disturbance. Adverse events (AEs) were evaluated at each visit.</p><p><strong>Results: </strong>Mean EASI score significantly decreased from 13.4 (95% CI 8.5-18.3) to 7.8 (95% CI 2.4-13.3) after 28 weeks (<i>p</i> = .002). Mean NRS pruritus significantly decreased from 6.5 (95% CI 4.9-8.2) to 4.8 (95% CI 3.0-6.6) after 28 weeks (<i>p</i> = .003). At week 16, 75.0% (95% CI 46.8-91.1) achieved EASI ≤7, and 50.0% (95% CI 25.4-74.6) achieved NRS pruritus ≤4. Overall, 31 AEs were reported in 10 patients (66.7%). Five patients (33.3%) discontinued treatment: two due to ineffectiveness, two due to AEs, and one due to laboratory monitoring problems.</p><p><strong>Conclusions: </strong>Our findings indicate that upadacitinib is effective and relatively safe for adolescents with moderate-to-severe AD; however, 33.3% discontinued treatment.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2539282"},"PeriodicalIF":3.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144755468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychosocial interventions for psoriasis: a Bayesian network meta-analysis.","authors":"Lingling Lu, Yujuan Xu, Meiling Shi, Aimin Liu","doi":"10.1080/09546634.2024.2427321","DOIUrl":"10.1080/09546634.2024.2427321","url":null,"abstract":"<p><strong>Background: </strong>Psoriasis impacts patients' mental and physical health, prompting interest in psychosocial interventions.</p><p><strong>Aim: </strong>To compare and rank different psychosocial interventions for psoriasis and their effects on well-being and mental health.</p><p><strong>Methods: </strong>A systematic search was conducted using Cochrane Library, EMBASE, Medline, and PsycINFO (<i>via</i> the OVID) from their inception to 6 February 2024. Trials investing in psychosocial therapy in psoriasis patients were included using A random-effects network meta-analysis (NMW) within a Bayesian framework focusing on dermatology life quality index (DLQI), depression, and anxiety, along with adherence to treatment. The risk of bias was assessed by the Cochrane Handbook.</p><p><strong>Results: </strong>Thirteen studies with 6 treatments and 1233 patients were included. The quality of the included studies was low. For DLQI, 9 studies were eligible, mindfulness + treatment as usual (TAU) was better than TAU (MD = -7.21, 95%CI [-14.89, 0.54]). Cognitive behavioral therapy (CBT) + TAU were more effective in improving HADS-anxiety (MD = -2.17, 95%CI [-3.86, -0.49]) and HADS-depression (MD = -1.58, 95%CI [-3.65, 0.68]). Regarding adherence, CBT + TAU (MD = 0.84, 95%CI [-0.62, 2.27]) ranked first, followed by motivational interviewing + TAU.</p><p><strong>Conclusion: </strong>We confirmed the effectiveness of psychosocial interventions on patients' well-being and mental health and recommended several interventions for clinical practice. However, the results should be cautiously interpreted, due to lacking high-quality and more replication studies.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2427321"},"PeriodicalIF":3.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144055975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of the combination therapy of CO₂ laser and thalidomide in cutaneous classic Kaposi's sarcoma.","authors":"Xianghui Li, Ramesh Sharma Poudel, Cunwei Cao, Gao Wei, Jingping Liu","doi":"10.1080/09546634.2025.2539290","DOIUrl":"10.1080/09546634.2025.2539290","url":null,"abstract":"<p><strong>Objective and significance: </strong>This study evaluates the efficacy and safety of a combined treatment approach using CO₂ laser therapy and oral Thalidomide for the management of skin lesions in patients with classic Kaposi's sarcoma (CKS).</p><p><strong>Methods: </strong>We conducted a prospective observational study at the First Affiliated Hospital of Guangxi Medical University, spanning from April 2021 to April 2023. The study focused on assessing the therapeutic outcomes in terms of macroscopic and microscopic changes in skin lesions before and after the treatment.</p><p><strong>Results: </strong>This study enrolled 10 patients with an average age of 62.8 years, who predominantly exhibited skin lesions on their lower limbs, with some involvement of the upper limbs. Throughout the 6-24 months follow-up period, patients were administered oral thalidomide at a dosage of 100 mg per day and underwent three CO₂ laser sessions on average. Post-treatment, complete resolution of Kaposi's sarcoma (KS) was observed in 9 out of 10 patients, with histopathology and dermoscopy showing no residual KS-related manifestations. Adverse reactions occurred in three patients (30%), including red marks, skin scars, and itching.</p><p><strong>Conclusion: </strong>The combination of CO₂ laser therapy with oral thalidomide offers a straightforward, efficacious, and safe treatment for cutaneous lesions in classic CKS patients.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2539290"},"PeriodicalIF":3.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144746625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of vitiligo in clinical practice: a cross-sectional survey among experts.","authors":"Jolien Duponselle, Marlide R Jukema, Albert Wolkerstorfer, Khaled Ezzedine, Iltefat Hamzavi, Julien Seneschal, Viktoria Eleftheriadou, Amit G Pandya, Amit Garg, Anand Ganesan, Boon Kee Goh, Davinder Parsad, Deepti Ghia, David Rosmarin, Giovanni Leone, Henry W Lim, Hyun Jeong Ju, Jung Min Bae, John Ferguson, Laila Benzekri, Marwa Abdallah, Markus Böhm, Mauro Picardo, Mehdi Rashighi, M Ramam, Michelle Rodrigues, Noufal Raboobee, Phyllis Spuls, Samia Esmat, Steven Tien Guan Thng, Thierry Passeron, Victor Huang, Reinhart Speeckaert, Nanja van Geel","doi":"10.1080/09546634.2025.2555984","DOIUrl":"https://doi.org/10.1080/09546634.2025.2555984","url":null,"abstract":"<p><strong>Background: </strong>The assessment of patient-centered outcomes in clinical practice is essential for optimal care. While a core domain set (CDS) for vitiligo clinical trials was established in 2015 (CDS for trials) to standardize outcomes, no CDS currently exists for clinical practice, resulting in inconsistent assessment complicating effective disease management.</p><p><strong>Objective: </strong>This study aimed to investigate outcomes and characteristics currently assessed by vitiligo experts in clinical practice and represents one of the steps toward developing a core outcome set (COS) including outcomes and outcome measurement instruments for clinical practice.</p><p><strong>Methods: </strong>A cross-sectional survey was conducted among 31 vitiligo experts from six continents. The survey consisted of 28 predefined outcomes and characteristics. Participants were given the opportunity to propose additional options, which were considered 'generally assessed' when assessed by ≥ 70%.</p><p><strong>Results: </strong>Six outcomes and 21 characteristics were 'generally assessed'. The most frequently chosen outcomes included vitiligo evolution, tolerability of treatment/adverse events, followed by disease activity and vitiligo extent.</p><p><strong>Conclusion: </strong>This study shows similarities but also remarkable differences in assessed outcomes compared to the CDS for clinical trials. These results serve as a preparatory step toward developing a COS for clinical practice with the involvement of expert and non-expert dermatologists and patients.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2555984"},"PeriodicalIF":3.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145277061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical observation of 10 cases of stable non-segmental vitiligo in adults treated with upadacitinib.","authors":"Mingzhu Yuan, Ruyi Li, Wen Zhang, Yi Sun","doi":"10.1080/09546634.2025.2492879","DOIUrl":"https://doi.org/10.1080/09546634.2025.2492879","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the efficacy and safety of upadacitinib in treating stable nonsegmental vitiligo in adults.</p><p><strong>Methods: </strong>Data were collected from adult patients with stable nonsegmental vitiligo treated with upadacitinib at Jingzhou Hospital of Yangtze University between November 2023 and November 2024. Treatment efficacy was compared at 8 and 16 weeks and any adverse reactions were recorded.</p><p><strong>Results: </strong>A total of 10 patients were included, 6 of whom also received 308 nm excimer laser therapy. A total of 200 lesions were observed, with 146 receiving additional laser therapy. After 8 weeks of treatment, 60.0% of lesions achieved at least 25% pigmentation, while 27.0% achieved more than 50% pigmentation. After 16 weeks, these rates increased to 78.0% and 52.5%, respectively. Treatment efficacy was greater at 16 weeks compared to 8 weeks (<i>p</i> < 0.001). Acral lesions showed lower response rates compared to lesions on the face, neck, trunk, and limbs (<i>p</i> < 0.05). There was no statistically significant difference in efficacy between upadacitinib monotherapy and combination therapy with phototherapy (<i>p</i> > 0.05). Among the 10 patients, 6 achieved over 50% improvement in total VASI score after 16 weeks, while 4 showed more than 75% improvement.</p><p><strong>Conclusion: </strong>Upadacitinib is safe and effective treatment for stable non-segmental vitiligo in adults.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2492879"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144065490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy analysis of blunt separation combined with uncrosslinked sodium hyaluronate compound solution injection for sunken upper eyelid treatment in Asians.","authors":"Qingmei Jin, Richeng Dong, Jiahui Zhi, Weilu Xu, Zhehu Jin, Chenglong Jin","doi":"10.1080/09546634.2025.2497370","DOIUrl":"https://doi.org/10.1080/09546634.2025.2497370","url":null,"abstract":"<p><strong>Aim of the study: </strong>Injectable fillers are a popular treatment for sunken upper eyelid (SUE) deformity, but their efficacy and duration are limited. This study evaluated the clinical efficacy and safety of blunt separation combined with an uncrosslinked sodium hyaluronate compound solution for treating SUE in Asians.</p><p><strong>Methods: </strong>Twenty-seven Chinese patients (22 women, five men) with SUE underwent blunt separation to loosen subcutaneous adhesions. After disrupting the dermal layer, an uncrosslinked sodium hyaluronate solution was injected to stimulate collagen regeneration. Symptom improvement, recurrence, safety, and patient satisfaction were assessed.</p><p><strong>Results: </strong>Park S grading scores significantly improved after-treatment, 6 months, and 1 year (<i>p</i> < 0.05) immediately. Patients experienced mild pain, erythema, and swelling. Four had post-treatment bruising, which resolved within 5-8 days. No other adverse events or recurrences were observed, and patient satisfaction was high.</p><p><strong>Conclusions: </strong>This single-arm trial suggests that blunt separation with uncrosslinked sodium hyaluronate is a safe and effective SUE treatment with minimal side effects, the findings indicate potential for clinical application.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2497370"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144065504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reshaping treatment paradigm in actinic keratosis by using a modified Delphi questionnaire.","authors":"Thomas Dirschka, Marco Ardigò, Maria Concetta Fargnoli, Carla Ferrándiz-Pulido, Yolanda Gilaberte, Ina Hadshiew, Ketty Peris, Rolf-Markus Szeimies","doi":"10.1080/09546634.2025.2487657","DOIUrl":"https://doi.org/10.1080/09546634.2025.2487657","url":null,"abstract":"<p><strong>Purpose: </strong>Actinic keratosis (AK) is the main precursor of invasive cutaneous squamous cell carcinoma (cSCC). Since it is impossible to predict which lesions will progress to cSCC, early treatment of AK is crucial. Although AK treatments are effective, some are associated with local skin reactions that may impact treatment compliance and effectiveness. The aim of this modified Delphi study was to review the efficacy and safety of the different AK treatments, gain an understanding of the dermatologists' perspectives on their use, and provide guidelines for clinical practice.</p><p><strong>Materials and methods: </strong>This document corresponds to a modified Delphi consensus survey, based on a literature review and a single round of questionnaire.</p><p><strong>Results: </strong>The Delphi questionnaire was completed by 73 dermatologists from Germany, Italy, and Spain. Agreement was achieved for 78% of statements, while 11% showed discrepancies or were rejected.</p><p><strong>Conclusions: </strong>Key findings emphasize the importance of patient-centered approaches and treatment attributes beyond efficacy (e.g. tolerability or adherence). Understanding the mechanisms of action of treatments is vital for managing patients' and clinicians' expectations and optimizing outcomes. Alternative strategies for evaluating efficacy, including the Actinic Keratosis Area and Severity Index (AKASI) score and lesion reduction from baseline, were also highlighted.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2487657"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144056466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is colloidal oat an effective emollient ingredient for the prevention and treatment of atopic dermatitis in infants?","authors":"Joseph F Fowler, Lin Ma, James Bergman, Paul Horowitz, Tina Lavender, Lawrence F Eichenfield, Zoe Draelos, Simon G Danby, Michael J Cork","doi":"10.1080/09546634.2025.2487945","DOIUrl":"https://doi.org/10.1080/09546634.2025.2487945","url":null,"abstract":"<p><strong>Background: </strong>Atopic dermatitis (AD) is a chronic inflammatory skin condition characterized by barrier dysfunction and immune dysregulation, often leading to increased allergen penetration, sensitization, and secondary infections. Colloidal oat emollients are widely used in adult AD management, but their role in pediatric AD treatment, prevention, and allergy modulation remains under investigation.</p><p><strong>Methods: </strong>A comprehensive literature review evaluated clinical and preclinical studies on colloidal oat-containing emollients in pediatric AD treatment and prevention. Studies assessing skin barrier function, immune modulation, AD prevention, food allergy risk, and healthcare utilization were included.</p><p><strong>Results: </strong>Colloidal oat emollients improved skin hydration, reduced transepidermal water loss (TEWL), and supported barrier repair, leading to fewer AD flares and reduced reliance on steroid treatments. Studies suggest that early, consistent use of advanced emollient formulations may lower AD incidence in high-risk infants and reduce food sensitization rates. Real-world data indicate that patients using colloidal oat emollients have fewer clinic visits and lower overall healthcare costs. Concerns about oat sensitization remain unsubstantiated in most studies.</p><p><strong>Conclusion: </strong>Colloidal oat emollients are effective, well-tolerated, and cost-efficient for pediatric AD management. Their barrier-restorative and anti-inflammatory properties may reduce AD and allergy risk. Future research should focus on head-to-head emollient comparisons to optimize treatment strategies.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2487945"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144061392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy analysis of 5-aminolevulinic acid photodynamic therapy for vulvar lichen sclerosus in women of childbearing age.","authors":"Lijuan Yang, Qian Shang, Dongning Zhu, Yu Jia, Chunyu Shi, Yanling Dang","doi":"10.1080/09546634.2025.2497362","DOIUrl":"https://doi.org/10.1080/09546634.2025.2497362","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the efficacy and long-term durability of 5-aminolevulinic acid photodynamic therapy (ALA-PDT) in treating vulvar lichen sclerosus (VLS) in women of childbearing age.</p><p><strong>Methods: </strong>Fifty-five patients with VLS who had failed long-term repeated pharmacological treatments (mean disease duration: 3.6 ± 1.4 years)were enrolled. All participants underwent four sessions of ALA-PDT. Follow-up evaluations were conducted for six months after treatment. Outcomes were assessed using the Cattaneo clinical symptom and sign score and the Dermatology Life Quality Index (DLQI) questionnaire at baseline, after four treatments, and at 3-6 months post-treatment.</p><p><strong>Results: </strong>At the 6-month follow-up, efficacy rates were 81.8% for pruritus relief, 67.3% for skin elasticity restoration, 63.6% for skin color improvement, and 72.7% for lesion area reduction. Pain was the only reported adverse reaction during treatment.</p><p><strong>Conclusion: </strong>20% ALA-PDT is a safe, effective, and durable therapeutic option for VLS with minimal side effects. Notably, it provides a viable alternative for patients unresponsive to conventional therapies.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2497362"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144032642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}